Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock ...

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned ...

Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious ...

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI ...

In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A ...

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one ...

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in ...

Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the ...